

31st July, 2012

(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended 30th June, 2012

We are enclosing a copy of the Unaudited Financial Results for the quarter ended 30th June, 2012 as required under clause 41 of the listing agreement. This has been approved at the meeting of the Board of Directors of the Company held today at the Registered Office at 3.00 p.m.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl.: as above

cc: (1) Central Depository Services (India) Ltd.
16th - 17th Floor, Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 023

(2) National Securities Depository Ltd.
Trade World, 4th Floor, Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel, Mumbai 400 013

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED 30TH JUNE 2012**

(₹ in crores)

Particulars	Quarter Ended			Year Ended
	30.06.2012	31.03.2012	30.06.2011	31.03.2012
	Unaudited			Audited
1. Income from operations				
a) Net Sales/Income from Operations (Net of excise duty)	1917.38	1814.05	1550.33	6807.68
b) Other Operating Income	40.81	51.52	32.42	169.82
Total income from operations (net)	1958.19	1865.57	1582.75	6977.50
2. Expenses				
a) Cost of materials consumed	550.70	623.15	541.04	2300.85
b) Purchases of stock-in-trade	151.85	117.43	148.41	555.55
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	29.87	31.90	(21.22)	11.24
d) Employee benefits expense	213.00	182.02	171.23	728.21
e) Depreciation and amortisation expense	72.82	70.46	70.25	282.07
f) Other expenses	472.92	512.29	382.42	1799.79
Total expenses	1491.16	1537.25	1292.13	5677.71
3. Profit (+)/Loss (-) from operations before other income and finance costs (1-2)	467.03	328.32	290.62	1299.79
4. Other Income	53.06	38.95	41.23	148.30
5. Profit (+)/Loss (-) before finance costs (3+4)	520.09	367.27	331.85	1448.09
6. Finance costs	1.09	2.25	11.96	26.63
7. Profit (+)/Loss (-) before tax (5-6)	519.00	365.02	319.89	1421.46
8. *Tax expense	118.24	73.28	66.55	297.50
9. Net Profit (+)/Loss (-) after tax (7-8)	400.76	291.74	253.34	1123.96
10. Paid-up equity share capital (Face Value ₹ 2 per share)	160.58	160.58	160.58	160.58
11. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				7380.73
12. Basic and Diluted Earnings per share (₹) **Not Annualised	** 4.99	** 3.63	** 3.16	14.00
A. PARTICULARS OF SHAREHOLDING				
1. Public shareholding				
- Number of shares	505565473	506720722	505135049	506720722
- Percentage of shareholding	62.97	63.11	62.91	63.11
2. Promoters and Promoter Group Shareholding				
a) Pledged/Encumbered				
- Number of shares	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL
b) Non-Encumbered				
- Number of shares	295485978	295485978	295485978	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	36.80	36.80	36.80	36.80

Particulars	Quarter Ended 30.06.2012
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	15
Disposed of during the quarter	15
Remaining unresolved at the end of the quarter	NIL

Notes:

1. The Company is essentially in the pharmaceutical business segment.
2. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by a separate order restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to ₹ 1654.92 crore (inclusive of principal amount for the period July 1995 to April 2009 and interest upto January 2012).
3. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
4. *Tax expense is inclusive of current tax and deferred tax.
5. The results for the quarter ended 30th June, 2012 have been subjected to Limited Review by the Statutory Auditors, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31st July, 2012.

Mumbai
31st July, 2012

By order of the Board
For CIPLA LIMITED


M. K. Hamied
Joint Managing Director